公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal productsused in cattle, sheep, goats, and swine production.
公司地址 450 ELANCO CIRCLE, INDIANAPOLIS, IN, USA, 46221
電話號碼 +1 877 352-6261
傳真號碼 --
公司網頁 https://www.elanco.com
員工數量 9400
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Ramiro Martin Cabral Executive Vice President and President of Elanco International 美元 620.00K 27/03/2025
Mr. David S. Kinard Executive Vice President, Human Resources, Corporate Communications and Administration -- 27/03/2025
Ms. Ellen de Brabander, PhD Executive Vice President, Innovation and Regulatory Affairs 美元 753.05K 27/03/2025
Mr. Rajeev A. Modi Executive Vice President, U.S. Pet Health and Global Digital Transformation -- 27/03/2025
Mr. Timothy J. Bettington Executive Vice President, Corporate Strategy and Market Development 美元 642.00K 27/03/2025
Ms. Grace McArdle Executive Vice President, Manufacturing and Quality -- 27/03/2025
Mr. James M. Meer Senior Vice President and Chief Accounting Officer -- 24/02/2026
Mr. Robert M. VanHimbergen Executive Vice President and Chief Financial Officer -- 24/02/2026
Ms. Shiv O'Neill Executive Vice President, General Counsel and Corporate Secretary -- 27/03/2025
Mr. Jose Manuel Correia de Simas, PhD Executive Vice President, U.S. Farm Animal Business -- 27/03/2025
Mr. Jeffrey N. Simmons President, Chief Executive Officer and Director 美元 1.20M 24/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Lawrence E. Kurzius Chairman of the Board 24/02/2026
Dr. Stacey Ma, PhD Independent Director 24/02/2026
Mr. Art A. Garcia Independent Director 24/02/2026
Mr. Kirk McDonald Independent Director 24/02/2026
Ms. Kapila Kapur Anand Independent Director 24/02/2026
Mr. Michael J. Harrington Independent Director 24/02/2026
Mr. R. David Hoover Independent Director 24/02/2026
Mr. Paul S. Herendeen Independent Director 24/02/2026
Dr. Deborah T. Kochevar, D.V.M.,PhD Independent Director 24/02/2026
Mr. Jeffrey N. Simmons President, Chief Executive Officer and Director 24/02/2026
Dr. Denise Vera Scots-Knight, PhD Independent Director 24/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:49)
代號 名稱 佔比% 持有日期
JHMLJHancock Multifactor Large Cap ETF0.001%27/02/2026
BUYOKraneShares Man Buyout Beta Index ETF0.001%27/02/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.001%27/02/2026
CVMCCalvert US Mid-Cp Cor Rspnb ETF0.001%27/02/2026
DEUSXtrackers Russell US Multifactor ETF0.001%26/02/2026
XCHGAB US Equity ETF0.001%27/02/2026
AVSUAvantis Responsible US Equity ETF0.001%28/02/2026
UMDDProShares UltraPro MidCap4000.001%27/02/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0005%27/02/2026
LCDSJPMorgan Fundamental Data Sci Lg Cor ETF0.0004%27/02/2026
VSLUApplied Finance Valuation LgCp ETF0.0004%27/02/2026
AVTMAvantis Total Equity Markets ETF0.0003%28/02/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.0003%27/02/2026
MFUSPIMCO RAFI Dyn Multi-Factor US Eq ETF0.0003%26/02/2026
AVIEAvantis Inflation Focused Equity ETF0.0001%28/02/2026
FEACFidelity Enhanced U.S. All-Cap Eq ETF0.0001%27/02/2026
CDEICalvert US Large-Cp Div, Eq AndIncETF0.00003%27/02/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.00002%27/02/2026
AUSFGlobal X Adaptive US Factor ETF<0.000001%06/11/2025
AVLVAvantis US Large Cap Value ETF<0.000001%27/09/2025
  1    2    3    4    5   6    7    8  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.